1 2

Ipamorelin & CJC-1295

Ipamorelin & CJC-1295

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$89.99
$89.99
Sale Sold out
Shipping calculated at checkout.
Product Options

Ipamorelin + CJC-1295 — Complementary GH Axis Research Blend

This combo pairs Ipamorelin (a selective ghrelin/GHSR-1a agonist) with CJC-1295 (a GHRH analogue, ±DAC). Together they’re used to study pituitary growth-hormone (GH) pulsatility, hypothalamic–pituitary regulation, and downstream IGF-1 biology in controlled research settings.

Component A — Ipamorelin
  • CAS: 170851-70-4 
  • PubChem CID: 9831659 
  • Sequence (pentapeptide): Aib-His-D-2-Nal-D-Phe-Lys-NH2 
  • Notes: Highly selective for GH release with minimal ACTH/cortisol or prolactin effects vs older GHRPs. 
Component B — CJC-1295 (GHRH analogue)
  • Forms: CJC-1295 with DAC (albumin-binding “Drug Affinity Complex”) and CJC-1295 no DAC / Mod GRF(1-29).
  • CAS (reported): with DAC 446262-90-4 ; no-DAC listings vary by substitution, commonly 446036-97-1 or 863288-34-0. 
  • Mechanism: Agonist at the GHRH receptor (GHRHR) on pituitary somatotrophs.
  • PK note: DAC prolongs half-life via albumin binding; no-DAC behaves like short-acting GHRH(1-29) analogues.
Why Use the Combo (Plain English)
  • Two switches, one output: CJC-1295 triggers the pituitary via GHRH, while Ipamorelin stimulates the ghrelin/GHSR pathway. Hitting both can amplify GH pulses vs either alone (synergy shown with GHRH + GHRPs/ghrelin). 
  • Clean signal: Ipamorelin is noted for selective GH release with low cortisol/prolactin cross-activation in studies—helpful for tidy readouts. 
  • Design flexibility: Choose no-DAC (short-acting pulses) or DAC (sustained exposure) to match your protocol window.

Key Study Themes — What’s Typically Tested

GHRH + GHS synergy on GH pulsatility
  • What’s tested: Co-administration of a GHRH analogue with a ghrelin mimetic; serial GH sampling and deconvolution analysis.
  • What changes: Greater peak GH and area-under-curve vs either agent alone in human and animal models. 
  • Why it matters: Models how dual hypothalamic inputs coordinate pituitary output, informing endocrine physiology and test paradigms. 
Selectivity & endocrine “cleanliness” with Ipamorelin
  • What’s tested: GH vs non-GH pituitary hormones under Ipamorelin exposure.
  • What changes: Minimal effects on ACTH/cortisol or prolactin at GH-effective doses in classic work. 
  • Why it matters: Helps isolate GH/IGF-1 axes without confounding adrenal or lactotroph signals.

Potential Research Applications

Endocrine Physiology

  • GH pulse profiling & deconvolution
  • Somatostatin “tone” and feedback experiments

Translational Models

  • IGF-1 kinetics and downstream signaling
  • Body-composition and protein-turnover readouts (animal models)

Comparative Pharmacology

  • CJC (DAC vs no-DAC) pulse vs exposure experiments
  • Ghrelin mimetic selectivity comparisons

Blend Options (Research Configurations)

Standard

  • 1:1 mass ratio (Ipamorelin:CJC)
  • Balanced GH pulse amplitude + duration

Pulse-Forward

  • 2:1 (Ipamorelin-heavy)
  • Emphasis on sharp peaks for sampling studies

Exposure-Forward

  • 1:2 (CJC-heavy; consider DAC)
  • Emphasis on sustained GH/IGF-1 windows

Design Notes

  • State form clearly (with DAC vs no-DAC) and vehicle/pH.
  • Pre-specify sampling times (e.g., frequent early draws for peak capture).
  • Document fed/fasted state and exercise, which modulate GH dynamics. 

Synergistic Peptides (for Study Design)

MOTS-c

  • Why pair: Energy-metabolism angle alongside GH/IGF-1 endpoints.
  • Angle: Combine mitochondrial metrics with GH pulse analysis.

IGF-1/Mechano-Pathway Probes

  • Why pair: Downstream pathway validation (e.g., AKT/mTOR phosphorylation).
  • Angle: Tissue-specific signaling with controlled GH patterns.

Controls

  • Include single-agent arms and vehicle to quantify additivity vs synergy.
  • Consider somatostatin analog controls to probe counter-regulation.

Known Concerns (Context)

  • Identifier variance (CJC): CAS numbers differ by form (DAC vs no-DAC) and specific substitutions; list the exact form in your methods. 
  • Assay design: GH biology is highly time-dependent; sparse sampling can miss peaks.
  • General: Sold for laboratory research use only; not for human consumption, medical, or veterinary use.

Specifications & Handling

  • Form: Lyophilized powders; blend ratio indicated on label
  • Purity (each): ≥ 98–99% (HPLC/MS verified)
  • Storage: ≤ −20 °C; dry, low-light; minimize freeze–thaw cycles
  • In solution: Prepare fresh aliquots; record vehicle, pH, and time-course
  • Packaging: Tamper-evident; research-only labeling

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

Ipamorelin + CJC-1295 Research Blend | Ghrelin (GHSR-1a) + GHRH Synergy | GH Pulsatility & IGF-1 Studies

Keywords: Ipamorelin, CJC-1295, CJC-1295 with DAC, Mod GRF(1-29), GHRH analogue, ghrelin mimetic, GHSR-1a, GH pulse, IGF-1, endocrine physiology, Base Peptides.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.
Keep Shopping